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Opioids are the main group of pharmacological agents used during the perioperative period and provide a
sedative and analgesic component. The observations of opioid consumption in West Europe indicate that this
group of drugs is widely used in chronic noncancer pain therapy.
Nearly 20 years ago, the first publications indicating that opioids, as an element of perioperative phar-
macotherapy in oncologic patients, increase the risk of tumor recurrence and affect further prognosis were
presented. The actual publications suggest that there are multifactorial, complex mechanisms underlying the
immunological impact and carcinogenesis promotion of opioids and that the intensity varies depending on the
type of opioid. There are also questions about the immunosuppressive effects among patients receiving opioids
in the treatment of chronic noncancer pain.
The aim of the review article is to present information about the action of opioids on the immune system in
carcinogenic settings and to define the clinical usefulness of this pharmacological phenomenon.
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’ INTRODUCTION
Opioids are the main group of pharmacological agents
used during general anesthesia and provide a sedative and
analgesic component. In addition to these two effects, it
should also be emphasized that these substances cause an
immunosuppressive effect and exacerbate this effect in the
perioperative period. Opioid-induced immunosuppression,
especially in oncologic patients, is a hot topic of current
perioperative pharmacology research. This is a new trend in
complex oncologic treatment: not only does the surgical
resection of the lesion begin the therapeutic process, but the
whole perioperative period, including the pharmacological
aspects of the method of anesthesia and postoperative
analgesia, is of great importance (1,2).
Nearly 20 years ago, the first publications indicating that
opioids affect prognosis in oncologic therapy were pre-
sented. Many authors demonstrated a reduced risk of tumor
recurrence connected with the use of regional anesthetic
techniques and limitation of opioid use in the perioperative
period. It has also been suggested that the intensity of these
effects varies depending on the type of opioid. This is
particularly important in cancer-related pain and in the
perioperative period, especially in patients with early-stage
cancer. The observations of opioid consumption in West
Europe indicate that this group of drugs is widely used in
chronic noncancer pain therapy. There are also questions about
the effects of the immunosuppressive mechanisms among
patients receiving opioids in the treatment of chronic noncancer
pain. The influence of opioids on the immune system and
carcinogenesis has not been fully explained. In view of the
increasing use of opioid drugs and their important place in
multimodal oncologic therapy, the connection of opioids with
the immune system and cancer has a crucial role (3,4).
It has also been suggested that the intensity of immuno-
suppressive effects varies depending on the type of opioid.
It was also described that in many tumor tissues, increased
expression of opioid receptors was observed, and their
accumulation was also associated with an increased risk of
cancer progression with metastasis. The presented reports
are a very important element of multidirectional cancer
therapy. With respect to such publications, the question
should be asked as to whether to limit the use of opioid
drugs in oncologic patients (3-5).
The aim is to present information about the mechanisms
underlying the influence of opioid drugs on the immune
system in a cancer setting and determine the clinical usefulness
of this phenomenon in multimodal oncologic treatment.
Opioid receptors
The first publications regarding the location of opioid
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1970s and 1980s indicated that these substances were
associated with the nervous system. However, subsequent
experimental studies have indicated that the opioid receptor
system is widely distributed in both peripheral and cen-
tral nervous system structures, in structures of ascending
(peripheral nerves, the spinal cord dorsal horn, the brain
stem, the thalamus, and the cortex) and descending pain
transmission pathways, in organs of the autonomic nervous
system and in the immune system. Recent publications
indicate that opioid receptors are also found in tissues
involved in the inflammatory process as well as in cancerous
tissues (5,6).
Opioid receptors are classified into the following groups:
the classic naloxone-sensitive receptors, mi opioid receptor
(MOR), delta opioid receptor (DOR), and kappa opioid
receptor (KOR), and nonclassic naloxone-insensitive recep-
tors (NORs). Receptor-specific interactions induce analgesic
effects; however, many authors have emphasized that only
MORs are associated with the effects leading to respiratory
depressive, tolerance-inducing and immunosuppressive
effects (7-10).
The effects of immunomodulation have been related to
interactions with MORs and NORs. The functions and sig-
nificance of MORs have been well understood and described.
The most important aspect related to NOR activation is
analgesic effects at the spinal cord level, and unlike other
opioid receptors, NORs do not contribute to the develop-
ment of respiratory depression and have minimal risk of
tolerance or addiction (11-14).
Opioids, immunity, and oxidative stress
In terms of elements of innate immunity, the activation
of opioid receptors results in a decrease in the number of
macrophages, reduced leukocyte migration to inflammatory
sites, decreased phagocytotic activity of macrophages,
decreased chemotaxis and superoxide production by neu-
trophils and macrophages, accelerated apoptosis of macro-
phages, weakened microbiological protection, and reduced
adhesion of leukocytes and endothelial cells. Other negative
effects have also been described in relation to mast cells,
dendritic cells, and natural killer (NK) cells. Opioids impair
intestinal barrier function and promote systemic infections
by increasing the sensitivity of gut epithelial cells to Toll-like
receptor activation with bacterial translocation. In addition,
opioid treatment changes the gut microbial composition and
induces the expansion of gram-positive pathogens. These
mechanisms promote the translocation of harmful pathogens
and result in the risk of systemic infection (6-8,12). Regarding
the elements of adaptive immunity, proliferative and
secretory hyperactivity of T helper cells (Th), increased
apoptosis of the subpopulation of Th1 cells with increased
differentiation of the subpopulation Th 2 cells, a decreased
Th1/Th2 ratio, a decreased CD4/CD8 Th ratio, and
decreased NK activity have been reported. In humoral
aspects, lower concentrations of interleukin 1 beta, inter-
leukin 2, tumor necrosis factor alpha and interferon-gamma
were described. Regarding B cells, decreased production of
antibodies, decreased activity in the expression of tissue
compatibility factors and proliferation, decreased mitotic
response after stimulation with bacterial antigen, increased
secretion of transforming growth factor beta, and other anti-
inflammatory cytokines and increased Tcell apoptosis due to
nuclear factor kappa B and the activator protein 1/nuclear
factor of activated T cells pathways have been observed. The
indirect mechanism of the interaction of opioid drugs with
the immune system has been associated with the neuroendo-
crine axis described as the hypothalamic–pituitary–adrenal
(HPA) axis. Opioid receptor activation in central nervous
system structures stimulates corticotropin-releasing hormone
secretion, which activates the production of adrenocortico-
tropic hormone in the anterior pituitary region, with the
final effect of producing glucocorticoids in the adrenal
cortex. The catecholamines excreted from the adrenal
glands showed depression of NK cell activity, as well as
decreased proliferation and differentiation of peripheral
blood lymphocytes. The effects associated with glucocorti-
costeroids are associated with the modulation of transcrip-
tion of genes related to both innate and adaptive immune
defense (13-17).
Other publications have also confirmed the multidirec-
tional role opioids play in carcinogenesis by regulating the
transcription of tumor growth factors and promoting capillary
formation and neovascularization of cancerous tissue. It has
been shown that the MORs regulate the proliferation and
migration of non-small-cell lung cancer cells through interac-
tions at the level of gene transcription: nonreceptor tyrosine
kinase (Src), associated binding protein 1 (Gab-1/GRB 2),
phosphatidylinositol-4,5-biphosphate 3-kinase catalytic
subunit alpha (PI3CA), signal transducer and activator of
transcription 3 (STAT 3), serine/threonine kinase 1 (Akt)
(18,19). Connolly et al. analyzed the expression of genes
connected with the analgesic effect of opioids in breast
tumor tissue and found that these genes play an important
role in cancer progression (20). The authors also identi-
fied a high level of MOR and DOR gene expression as
conferring a high risk of metastasis. Increased expression
of MORs in prostate tumor tissues or lung cancer was a
risk factor for disease progression, unfavorable prognosis
and increased demand for opioid drugs in the postopera-
tive period (21,22).
Another mechanism of opioid-regulated carcinogenesis
is connected with microRNA function (miRNA), which are
endogenous factors, including noncoding RNAs, which
regulate gene expression and posttranscriptional modifica-
tion. It was described that opioids induce upregulation of
miRNA 221 and the let-7 family, which are important factors
in carcinogenesis and apoptosis, and downregulation of
miRNA-92, which is crucial for proliferation, invasion, and
migration (23,24).
The next mechanism of opioid-induced immunosuppres-
sion is connected with oxidative stress and reactive oxygen
species (ROS) function. ROS are known as the most impor-
tant mutagenic factor, causing DNA damage and contribut-
ing to malignant transformation. The ROS concentration is a
final balance of oxidative and antioxidative processes. Their
low stability and high diversity of reactions complicate their
intracellular and fluid measurements, and many other
biochemical markers have been described as predictors of
oxidative balance (superoxide dismutase, catalase, glutathione
peroxidase, and ascorbic acid). The newest laboratory measures
are total oxidative capacity and total antioxidative capacity,
which present a summary of all mechanisms (3,6).
Clinical aspects
The opioid-induced immunosuppression phenomenon in
anesthesia and acute postoperative pain is a current topic.
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Although no relevant recommendations have been developed
yet, methods of low-dose opioid or even nonopioid anesthesia,
multimodal perioperative analgesia with the use of local
anesthetics and regional analgesia are performed. It seems that
in the perioperative period, many pharmacological substances
used during general anesthesia cause immunosuppression
through modulation of the oxidative balance and activation of
HPA and the sympathomimetic system. These mechanisms
have been reported to increase ROS concentration and release
catecholamines and prostaglandins, which in turn induce the
secretion of chemokines, immunosuppressive cytokines and
proinflammatory cytokines that promote angiogenesis in
tumor tissues and metastases (12,14,16).
The clinical effects of opioid-induced immunosuppression
have been described in many aspects. It was shown that
opioid analgesia deprived the cytotoxic function of NK
lymphocytes more than ketorolac did, and the immunosup-
pressive effect assessed by the cytotoxicity of NK lympho-
cytes was stronger after using morphine and had a smaller
effect after using oxycodone than after using opioids (25,26).
Combined general anesthesia based on opioid analgesia
increased the expression of MORs in breast tumor tissues
compared to total intravenous anesthesia with propofol and
the technique of paravertebral analgesia with bupivacaine
solutions (16).
The phenomenon of increased expression of opioid recep-
tors in gynecologic cancers and the effect of opioid use in the
perioperative period on prognosis have also been described.
Levins et al. showed that MOR expression on breast cancer
cells was higher in patients who underwent combined vola-
tile anesthesia with perioperative opioid analgesia. Authors
suggested that administration of propofol, a paravertebral
anesthetic, without opioids decreased MOR expression.
A retrospective analysis of the course of treatment of patients
with ovarian cancer demonstrated that nonopioid analgesia,
epidural anesthesia and the continuation of this method in
the perioperative period may reduce mortality after 3 and
5 years of observation (16).
An important aspect of immunosuppression associated
with the use of opioids in cancer patients is the risk of
infection. Total daily opioid dose was an independent factor
that influenced the development of infection in opioid mono-
therapy in cancer patients, and the risk for developing
infection increased by 2% per 10 mg increase in an oral
morphine equivalent (27).
Opioid therapy is also used as an element in pharma-
cotherapy for neuropathic pain, which very often persists as
a consequence of chemotherapy, radiotherapy or cancer-
related neuropathy. The pathogenesis of neuropathic pain
points to multifactorial influences with a strongly expressed
component of excessive immune activation. In these clinical
situations, the opioid-induced immunosuppression phenom-
enon has a crucial and beneficial effect (10,15).
A separate issue is the risk of developing cancer in natural
opioid users and among patients with chronic noncancer
pain. Prolonged use of opium or its derivatives has been
reported to be an important risk factor for oral cavity cancers,
upper gastrointestinal tract cancers, pancreatic cancers, and
bladder, kidney, larynx, pharynx and lung cancers (28-33).
The role of opioid administration on the human immune
system and cancer progression cannot be unequivocally asses-
sed. Despite many observational and experimental studies,
these conclusions are contentious. A serious limitation of the
assessment of the clinical usefulness is the biological diversity
of tumors. Most publications presenting the topic of the
influence of opioid drugs on the course of cancer are based
on studies of gastrointestinal tract, lung, prostate and
breast cancer. In connection with epidemiological data, it is
extremely important to assess the data of opioid influence
on the progression of the most frequently occurring and
poorest prognosis cancers (34-37).
Opioid tolerance is another important clinical aspect of
immunosuppression. Approximately 60% of patients develop
drug tolerance during opioid therapy. However, the crucial
mechanisms are not completely understood, and the role of
microglia and astrocyte activation is the newest theory. A key
point is that opioids have direct effects on non-neuronal cells,
in particular, mast cells, astrocytes, and microglia. Mast cell
activation releases numerous cytokines (tumor necrosis factor,
interleukin-1, and tryptase) and pronociceptive substances,
such as substance P, that contribute to the exacerbation of
proinflammatory processes and nociception. Indeed, glial
cell-produced chemokines decrease the expression of receptors
to antinociceptive mediators (gamma-aminobutyric acid -
GABA) and increase the number of pronociceptive media-
tors (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropio-
nic acid – AMPA; and N-methyl-D-aspartate - NMDA),
decrease glutamate transporter proteins, and decrease out-
ward potassium currents. Many authors have shown that
both acute and chronic opioid administration, due to
microglia and astrocyte activation and increased levels of
pronociceptive stimulation mediators, require an increased
demand for opioid consumption and lead to the develop-
ment of opioid tolerance (38,39).
Opioids lead to immunosuppression via many mechan-
isms, but not all of them induce the same immune profile.
A strong modulating effect has been demonstrated for
codeine, methadone, morphine, fentanyl, sufentanil, and remi-
fentanil, and a weak modulating effect has been demonstrated
for oxycodone, tramadol, and hydromorphone. The smallest
immunomodulatory effect was noted for buprenorphine
(40,41). Most publications describe the immunosuppres-
sive effect with respect to the use of morphine. A number
of mechanisms for the effects of morphine on immunity
have been described. Morphine induces immune suppres-
sion by directly regulating adaptive and innate cells,
including NK cells, macrophages, mast cells, B cells and
T cells. Additionally, morphine administration due to indirect
mechanisms connected with central nervous system structures
and the HPA axis suppressed NK cell cytotoxicity and
lymphoproliferation (42,43). Sacerdote et al. (40) described
that chemical structure is a crucial point of immunosup-
pression: the C6 carbonyl substitution, together with the
presence of a C7-C8 single bond, potentiates the antinocicep-
tive effect but minimizes immunosuppression. This chemical
construction is characteristic of hydromorphone and oxyco-
done. Indeed, the single substitution of an allyl on the
piperidine ring resulted in a molecule that antagonized the
antinociceptive effect but maintained the immunosuppres-
sive effect. Wodehouse et al. (44) presented that morphine
significantly increased the interleukin-6 concentration and
suppressed NK cell cytotoxicity after gynecological opera-
tion, and gene expression profiles suggest that morphine was
more immunosuppressive than oxycodone and a nonopioid
control analgesic. It has been described that remifentanil-
based anesthesia attenuates leucocyte and neutrophil counts
during mastectomy (45). Buprenorphine is an opioid that has
the smallest immunosuppressive effect, and many authors
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have suggested considering buprenorphine as a first-line
analgesic (46).
Another important clinical issue associated with the opioid-
induced immunosuppression is the formation of hyperalgesia.
Classically, analgesic doses of morphine activate G mole-
cules of opioid receptor, and inhibite adenylyl cyclase
activity. Suprisingly, morphine administration at very low
doses induces a parodoxical effect with increase neuronal
excitability with creation of hyperalgesia. It was explained
that specific activation of non-neural cells in low-doses
opioid therapy increases level of pronociceptive stimulation
mediators. Inadequate postoperative pain control result-
ing from the use of inappropriate doses of opioids results
in persistent postoperative chronic pain (47). Currently,
in order to limit the use of opioids, it is recommended
to conduct polypharmacotherapy using multidirectional
action of non-opioid analgesics and adjuvants (anti-
convulsants, antidepressants, lidocaine, ketamine, magne-
sium) using their synergistic and additive effects, and to
reduce the use of opioid drugs to severe pain, and limit
duration of therapy. Moreover, in experimental studies, the
natural fatty-acid was recently identified as an endogen-
ous molecule that minimize antinociceptive and immuno-
suppressive effects of morphine. It was decribed that
PEA – N-Palmitoylethanol-amine minimizes the onset of
morphine tolerance, decrease activation of glial cells and
stopped phenomenon of tolerance, inhibited inflammation
and mast cell degranulation (48).
’ CONCLUSIONS
The topic of opioid influence on the immune system and
carcinogenesis is an important point of acute and chronic
pain pharmacotherapy. It should be assumed that this issue
is less relevant for patients with cancer at the stage of
palliative medicine, when multidirectional medical activities,
including pharmacological treatments, are aimed to ensure
quality of life. The subject of opioid influence on the devel-
opment and progression of neoplastic disease is a very
new topic, and at the moment, most publications concern the
use of these substances during surgical procedures and
as perioperative pharmacotherapy. At present, no precise
recommendations have been made to limit opioids in the
perioperative period in oncologic patients or during any
other period of oncologic therapy. However, methods of
low-opioid and nonopioid anesthesia have already been
developed, and a number of studies indicate that there are
possibilities to provide an adequate level of analgesia with
proper perioperative safety while limiting the use of opioids.
Knowledge about the relationships between long-term
opioid intake in noncancer chronic pain pharmacotherapy
and the development of cancer is incomplete, but current
publications increasingly indicate that patients in these
settings are at risk of developing cancer.
In conclusion, knowledge about the immunosuppressive
effects and carcinogenesis associated with the use of opioids
suggests that there are multifactorial, complex mechanisms
underlying the immunological and oxidative stress impacts
and carcinogenesis promotion of opioids and that the inten-
sity varies depending on the type of opioid. It should be
emphasized that current publications point to limiting the
use of opioids in acute and chronic pain treatment. In light of
the presented publications, it can be stated that there are
valid premises for modifying clinical practice.
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